Search
Displaying 451–460 of 645 for “retinal diseases”
-
MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial
Research NewsThe MeiraGTx gene therapy involves injection of healthy copies of RPGR underneath the retina. The RPGR copies are contained in a human-engineered virus — known as an adeno-associated virus or AAV — designed to readily penetrate retinal cells to deliver the therapeutic genetic cargo.
-
FFB-CRI Launching Natural History Study for People with USH2A Mutations
Research NewsThe study — known as RUSH2A (“R” stands for “rate of progression”) — is beginning in spring 2017 and will take place at about 20 clinical sites around the world. RUSH2A investigators will use a variety of technologies to monitor changes in vision and retinal structure to document and analyze disease progression.
-
Building a Wiring Diagram for the Retina to Help Researchers Save and Restore Vision
Research NewsUnderstanding the pathways of the retinal neural network — and how they are rewired with aging and disease — is helpful in trying to save and restore vision.
-
DHA and EPA for Stargardt Disease — an Evolving Story
Research NewsThese healthy fats have exciting potential for treating a wide range of retinal degenerations and other health conditions.
-
Tempering the Immune System to Save Vision
Research NewsGreat progress is being made in identifying targets for therapies, including using the body’s own protective systems to keep the photoreceptors alive.
-
Eva Lou Schroeder Watson's Enduring Legacy
Beacon StoriesEva Watson’s life was marked by her dedication to advancing medical research for blinding diseases, and her generous bequest to the Foundation Fighting Blindness ensures her advocacy will endure. Her story highlights the profound impact of her contributions to driving treatments and cures for blinding diseases.
-
VISIONS 2026: United in Vision
The United in Vision 2026 conference unites two prestigious events—the Foundation Fighting Blindness VISIONS conference and the Retinal International World Congress—into one extraordinary global gathering. Scheduled from Wednesday, June 10, to Saturday, June 13, 2026, at the Omni Fort Worth Hotel and Fort Worth Convention Center in Fort Worth, Texas.
-
Antabuse Moves into Clinical Trial for People with RP
Research NewsResearchers believe the FDA-approved drug can reduce the hyperactivity of ganglion cells to improve vision.
-
Research News
No serious adverse events were reported. One patient had encouraging improvement in retinal sensitivity.
-
Eye on the Cure Podcast | Episode 61: Dr. Jose Sahel
Eye on the CureDr. Jose Sahel, one of the most honored and accomplished leaders in the retinal disease research space, talks with host Ben Shaberman about his establishment and leadership of renowned ophthalmology clinical research centers at the University of Pittsburgh Medical Center and Institut de la Vision in Paris. They also discuss emerging inherited retinal disease therapies from SparingVision, a biotech co-founded by Dr. Sahel.
.png)
